A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Trial Profile

A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 09 Jan 2017 Results of this bioavailability study and it's extension part published in the Journal of Clinical Pharmacology.
    • 22 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top